Article Text

Download PDFPDF

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
  1. Robert L Ferris1,
  2. Caroline Even2,
  3. Robert Haddad3,
  4. Makoto Tahara4,
  5. Trishna Goswami5,
  6. April Franks5,
  7. Ugochi Emeribe5,
  8. Anthony Jarkowski III5,
  9. Giovanni Melillo5 and
  10. Lisa Licitra6
  1. Aff1 grid.21925.3d0000000419369000Department of Otolaryngology and Cancer Immunology ProgramUniversity of Pittsburgh Cancer Institute Pittsburg PA USA
  2. Aff2 grid.14925.3b0000000122849388Institut Gustave-Roussy Villejuif France
  3. Aff3 grid.65499.370000000121069910Dana Farber Cancer Institute Boston MA USA
  4. Aff4 grid.272242.30000000121685385National Cancer Center Hospital East Kashiwa Japan
  5. Aff5 grid.418152.bAstraZeneca Gaithersburg MD USA
  6. Aff6 grid.417893.00000000108072568Fondazione IRCCS Instituto Nazionale dei Tumori Milan Italy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Patients with R/M SCCHN have a poor prognosis, and current therapies used after failure of first-line platinum-based chemotherapy provide transient, limited benefit. SCCHN tumors are highly immunosuppressive and evade immune detection by exploiting inhibitory immune checkpoints such as the programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) axis. High mutational load and their relationship to human papillomavirus (HPV) infection may make these tumors amenable to immunotherapy. Durvalumab is a selective, human IgG1 mAb that blocks binding of PD-L1: to PD-1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM). Tremelimumab is a selective human IgG2 mAb inhibitor of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). The PD-1 and CTLA-4 pathways are non-redundant and targeting both induces synergistic antitumor effects, according to preclinical data, and was found to be active and tolerable in a Phase Ib study in patients with NSCLC (NCT02000947). Durvalumab monotherapy has also shown preliminary antitumor activity in a Phase I/II study in patients with solid tumors, including a SCCHN cohort (NCT01693562). In a comprehensive clinical development program of durvalumab in SCCHN, the Phase III EAGLE study (NCT02369874) will investigate the efficacy and safety of durvalumab as monotherapy or in combination with tremelimumab versus SoC.


In this Phase III, open-label, multicenter, international study, 720 patients with PD-L1+ and PD-L1 R/M SCCHN will be randomized (1:1:1) to receive durvalumab (10 mg/kg IV for up to 12 months); tremelimumab (1 mg/kg IV) plus durvalumab (20 mg/kg IV for up to 12 months); or SoC (cetuximab, taxane, methotrexate, or fluoropyrimidine) (Figure 1). Stratification factors include PD-L1 status, HPV status and smoking history. Eligible patients are immunotherapy naïve and have progressed during or after treatment with a platinum-containing regimen for R/M disease or progressed within 6 months of multimodality therapy containing platinum. Co-primary endpoints are progression-free survival (PFS; RECIST v1.1), based on independent central review and overall survival (OS). Secondary outcomes will assess objective response rate, disease control rate, duration of response, and proportion of patients alive and progression free at 6 and 12 months (using RECIST v1.1 and immune-related RECIST criteria); safety (CTCAE v4.03) and tolerability; and health-related quality of life. Exploratory outcomes include pharmacokinetics, immunogenicity, and potential biomarkers that may influence the progression of cancer and/or prospectively identify patients likely to respond to treatment. Recruitment is underway.


Trial registration identifier NCT02369874.